v3.26.1
Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)
$ in Thousands
Total
ATM Offering Program
Registered Direct Offering
Total ImmunityBio Stockholders’ Deficit
Total ImmunityBio Stockholders’ Deficit
ATM Offering Program
Total ImmunityBio Stockholders’ Deficit
Registered Direct Offering
Common Stock
Common Stock
ATM Offering Program
Common Stock
Registered Direct Offering
Additional Paid-in Capital
Additional Paid-in Capital
ATM Offering Program
Additional Paid-in Capital
Registered Direct Offering
Accumulated Deficit
Accumulated Other Comprehensive Income
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2024             852,904,340                
Beginning balance at Dec. 31, 2024 $ (488,129)     $ (489,098)     $ 85     $ 2,884,867     $ (3,375,248) $ 1,198 $ 969
Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward]                              
Stock-based compensation expense 9,537     9,537           9,537          
Exercise of stock options (in shares)             110,020                
Exercise of stock options 220     220           220          
Vesting of RSUs (in shares)             901,713                
Net share settlement for RSUs vesting (in shares)             (359,880)                
Net share settlement for RSUs vesting (1,202)     (1,202)           (1,202)          
Other comprehensive income (loss), net of tax 18,758     18,758                   18,758  
Net loss (129,666)     (129,646)                 (129,646)   (20)
Ending balance (in shares) at Mar. 31, 2025             853,556,193                
Ending balance at Mar. 31, 2025 (590,482)     (591,431)     $ 85     2,893,422     (3,504,894) 19,956 949
Beginning balance (in shares) at Dec. 31, 2024             852,904,340                
Beginning balance at Dec. 31, 2024 (488,129)     (489,098)     $ 85     2,884,867     (3,375,248) 1,198 969
Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward]                              
Other comprehensive income (loss), net of tax 11,370                            
Net loss (222,240)                            
Ending balance (in shares) at Jun. 30, 2025             915,625,053                
Ending balance at Jun. 30, 2025 (569,819)     (570,749)     $ 91     3,014,041     (3,597,449) 12,568 930
Beginning balance (in shares) at Mar. 31, 2025             853,556,193                
Beginning balance at Mar. 31, 2025 (590,482)     (591,431)     $ 85     2,893,422     (3,504,894) 19,956 949
Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward]                              
Issuance of common stock/equity offering, net of commissions and offering costs (in shares)               32,854,486 29,024,768            
Issuance of common stock/equity offering, net of commissions and offering costs   $ 98,248 $ 13,051   $ 98,248 $ 13,051   $ 3 $ 3   $ 98,245 $ 13,048      
Stock-based compensation expense 9,648     9,648           9,648          
Vesting of RSUs (in shares)             297,223                
Net share settlement for RSUs vesting (in shares)             (107,617)                
Net share settlement for RSUs vesting (322)     (322)           (322)          
Other comprehensive income (loss), net of tax (7,388)     (7,388)                   (7,388)  
Net loss (92,574)     (92,555)                 (92,555)   (19)
Ending balance (in shares) at Jun. 30, 2025             915,625,053                
Ending balance at Jun. 30, 2025 $ (569,819)     (570,749)     $ 91     3,014,041     (3,597,449) 12,568 930
Beginning balance (in shares) at Dec. 31, 2025 1,011,800,008           1,011,800,008                
Beginning balance at Dec. 31, 2025 $ (499,574)     (500,469)     $ 101     3,197,120     (3,726,646) 28,956 895
Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward]                              
Issuance of common stock/equity offering, net of commissions and offering costs (in shares)               12,280,637              
Issuance of common stock/equity offering, net of commissions and offering costs   102,091     102,091     $ 1     102,090        
Conversion of related-party convertible notes (in shares)             4,606,596                
Conversion of related-party convertible note 35,332     35,332           35,332          
Stock-based compensation expense 8,169     8,169           8,169          
Exercise of stock options (in shares)             233,749                
Exercise of stock options 971     971           971          
Vesting of RSUs (in shares)             2,144,738                
Net share settlement for RSUs vesting (in shares)             (916,017)                
Net share settlement for RSUs vesting (6,994)     (6,994)           (6,994)          
Exercise of warrants (in shares)             17,191,435                
Exercise of warrants 125,179     125,179     $ 2     125,177          
Other comprehensive income (loss), net of tax (1,503)     (1,503)                   (1,503)  
Net loss (632,797)     (632,782)                 (632,782)   (15)
Ending balance (in shares) at Mar. 31, 2026             1,047,341,146                
Ending balance at Mar. 31, 2026 $ (869,126)     (870,006)     $ 104     3,461,865     (4,359,428) 27,453 880
Beginning balance (in shares) at Dec. 31, 2025 1,011,800,008           1,011,800,008                
Beginning balance at Dec. 31, 2025 $ (499,574)     (500,469)     $ 101     3,197,120     (3,726,646) 28,956 895
Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward]                              
Exercise of stock options (in shares) 409,276                            
Other comprehensive income (loss), net of tax $ (1,672)                            
Net loss $ (863,187)                            
Ending balance (in shares) at Jun. 30, 2026 1,053,221,645           1,053,221,645                
Ending balance at Jun. 30, 2026 $ (1,045,761)     (1,046,629)     $ 105     3,515,788     (4,589,806) 27,284 868
Beginning balance (in shares) at Mar. 31, 2026             1,047,341,146                
Beginning balance at Mar. 31, 2026 (869,126)     (870,006)     $ 104     3,461,865     (4,359,428) 27,453 880
Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward]                              
Issuance of common stock/equity offering, net of commissions and offering costs (in shares)               5,624,053              
Issuance of common stock/equity offering, net of commissions and offering costs   $ 45,059     $ 45,059     $ 1     $ 45,058        
Stock-based compensation expense 8,518     8,518           8,518          
Exercise of stock options (in shares)             175,527                
Exercise of stock options 666     666           666          
Vesting of RSUs (in shares)             126,325                
Net share settlement for RSUs vesting (in shares)             (45,406)                
Net share settlement for RSUs vesting (319)     (319)           (319)          
Other comprehensive income (loss), net of tax (169)     (169)                   (169)  
Net loss $ (230,390)     (230,378)                 (230,378)   (12)
Ending balance (in shares) at Jun. 30, 2026 1,053,221,645           1,053,221,645                
Ending balance at Jun. 30, 2026 $ (1,045,761)     $ (1,046,629)     $ 105     $ 3,515,788     $ (4,589,806) $ 27,284 $ 868